Cord plasma eye drops to treat neuropathic corneal pain
Official title: Evaluation of the Clinical Efficacy and Mechanisms of Cord Plasma Eye Drops in the Treatment of Neuropathic Corneal Pain
Run by Singapore Eye Research Institute · NCT07566806 · Data updated 2026-11-12
This trial will test whether cord plasma eye drops can reduce long-lasting nerve-related corneal pain in people with evidence of corneal nerve damage.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 21 Years and up |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | Singapore Eye Research Institute Academic / other |
| Locations | 1 site (Singapore, Singapore) |
| Status | Recruiting |
| Started | September 16, 2023 |
| Main results expected | September 15, 2026 |
| Study ends | September 15, 2027 |
| Registry record updated | May 5, 2026 |
| Trial ID | NCT07566806 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients with at least three months of neuropathic corneal pain symptoms, corneal nerve abnormalities on IVCM, minimal corneal staining, and willingness to use cord plasma eye drops.
✕Probably not a fit
Patients with active ocular surface infection, epithelial defects, or primarily nociceptive (non-neuropathic) pain are unlikely to benefit from this treatment.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a single-center interventional trial at the Singapore Eye Research Institute testing topical cord plasma eye drops in patients with neuropathic corneal pain lasting at least three months and corneal nerve abnormalities on in vivo confocal microscopy. Participants receive cord plasma eye drops and are followed for changes in pain symptoms, corneal nerve imaging (IVCM), and tear mediators to explore both clinical effect and mechanisms. Key eligibility requires persistent neuropathic symptoms, minimal surface staining, and imaging evidence of nerve damage; active ocular surface infection or epithelial defects are excluded. The study aims to determine whether the drops provide neurotrophic and anti-neuroinflammatory benefit beyond standard dry eye treatments.
Why it matters
Potential benefit: If successful, cord plasma eye drops could reduce neuropathic corneal pain and promote corneal nerve recovery for patients who do not respond to conventional treatments.
How similar studies have gone: Blood-derived eye drops (serum/plasma) have shown benefit for some ocular surface disorders, but applying cord plasma specifically for neuropathic corneal pain is relatively novel and not well-established.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Persistent ocular pain or pain-like symptoms, including burning sensation, allodynia, photoallodynia, stinging, hyperalgesia, throbbing, shooting, sharp, cramping, gnawing, or a feeling of electric shock, with a minimum score of 30% for more than 3 questions in the OPAS questionnaire (see below section for OPAS questionnaire), for at least 3 months; 2. Presence of corneal nerve abnormalities, including microneuromas, beading, nerve tortuosity, decreased in corneal nerve fiber density (CNFD) or corneal nerve fiber length (CNFL), on IVCM images; 3. Minimal or no ocular surface fluorescein staining, with the National Eye Institute (NEI) and ocular surface Oxford score \<2; 4. Patients who will receive cord plasma eye drops treatment Exclusion Criteria: 1. Presence of active ocular surface diseases, such as active infective keratitis, the presence of epithelial defect or any other conditions that may cause nociceptive pain 2. Active anterior or posterior blepharitis; 3. Presence of concomitant ocular diseases that may cause ocular pain, such as uveitis or other ocular inflammatory diseases; 4. Concurrent treatment with immunosuppressants, such as topical cyclosporin or steroid eye drops 5. Concurrent use of oral Nonsteroidal anti-inflammatory drugs (NSAID) or other medications that may affect the pain scores
Where it's running
-
Singapore Eye Research Institute
Singapore, Singapore, Singapore Recruiting
Study contacts
- Study coordinator: Yu-Chi Liu, PhD
- Email: liu.yu.chi@snec.com.sg
- Phone: 65 65767493
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Neuropathic Pain Severity in Lumbar Spinal Stenosis and Its Link to Radiology
This study will test how severe neuropathic pain is in adults with lumbar spinal stenosis and see if it relates to MRI findings and other clinical features.
-
Virtual Reality-Based Hypnotherapy to Help Pain, Sleep, and Mood in Spinal Cord Injury
Adults with spinal cord injury will try adding short VR-based hypnotherapy sessions to their standard physiotherapy to see if it reduces pain and improves sleep and mood.
-
Extended-release Pregabalin for nerve pain from diabetes or shingles
This phase 3 study tests an extended-release form of pregabalin to see if it reduces nerve-pain symptoms in adults with diabetic neuropathy or postherpetic neuralgia.
-
High-Intensity Peripheral Magnetic Stimulation for Traumatic Nerve Injury
This study tests whether adding high-intensity peripheral magnetic stimulation to a structured exercise program can reduce pain and improve function for adults with a traumatic peripheral nerve injury.
-
Hematological clues and how patients respond to nerve blocks for neuropathic pain
This study looks at blood inflammation markers to see if they relate to how well people with neuropathic pain respond to sympathetic nerve blocks.
-
Comparing different NSAIDs plus home exercises for frozen shoulder
This will test whether taking one of several NSAIDs (diclofenac, meloxicam, or indomethacin) together with home shoulder exercises helps adults aged 18–75 with frozen shoulder and whether pain type changes the benefit.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.